PG-102

Asset

Activates GLP-1 and GLP-2 receptors through a bispecific Fc fusion protein to improve glycemic control.

Stage
Phase 2
Modality
Other
Target
GLP1R
1
Indication
1
Trial
1
Developer

Indications

1
  • Type 2 diabetes

    Phase 2, doi.org, 5 Jun 2026

In the full profile

  • Targets and what it contains2
  • Owner and partners1
  • Trials1
  • Evidence for its targets3
  • Competitors12
  • Signals3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets